Use of momelotinib (MMB) appears to be more effective than danazol (DAN) in symptomatic and anemic myelofibrosis (MF) patients, according to a study presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.
In this study, researchers led by Ruben A. Mesa and colleagues assessed 130 patients with primary or post-ET/PV MF, DIPSS high risk, Int-2, or Int-1, MF Symptom Assessment Form Total Symptom Score (MFSAF TSS) ≥10, Hgb <10 g/dL, prior JAKi for ≥90 days, or ≥28 days if RBC transfusions ≥4 units in 8 weeks or Gr 3/4 thrombocytopenia, anemia, or hematoma; palpable spleen ≥5 cm, the researchers noted.
The key outcome measure was defined as TSS response (≥50% reduction from baseline [BL]) rate at week 24. Secondary endpoints were specified as RBC transfusion independence (TI) rate, splenic response rate (SRR; ≥25% reduction in volume from BL), change from BL in TSS, SRR (≥35% reduction from BL) and rate of zero transfusions since BL.
The researchers showed that all primary and key secondary endpoints were met with respect to comparing MMB versus DAN on key symptom, anemia, and spleen volume endpoints at 24 weeks. They concluded that: “In symptomatic and anemic MF pts, MMB was superior to DAN for symptom responses, transfusion requirements, and spleen responses with comparable safety and favorable survival. MMB may address a critical unmet need, particularly in MF pts with anemia.